The startup develops small molecules and single-strain live biotherapeutics targeting inflammatory diseases, utilizing novel mechanisms of action to enhance treatment efficacy. By focusing on debilitating inflammatory conditions, the company aims to provide effective therapeutic options that improve patient health outcomes.
Funding
$130M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for chronic and progressive inflammatory diseases often fail to halt disease progression or pose significant safety risks to patients. There is a need for more effective and targeted therapies to address a wide range of inflammatory conditions.
Solution
Adiso Therapeutics is developing a pipeline of multi-modal agents with novel mechanisms of action and a precision therapeutic approach to treat inflammatory diseases. Their pipeline includes small molecules and single-strain live biotherapeutic products (SS-LBP) designed to modulate inflammation in a highly differentiated way. These therapies aim to provide improved treatment options for patients and their families, addressing the limitations of existing approaches.
Target Audience
The primary target audience includes patients suffering from chronic and progressive inflammatory diseases, as well as their families and healthcare providers seeking more effective treatment options.
Features
- ADS051: An oral, gut-restricted small molecule that modulates neutrophil trafficking and activation for ulcerative colitis, currently in Phase 2 development.
- ADS032: A dual inflammasome inhibitor (NLRP1 & NLRP3) small molecule in advanced pre-clinical development for respiratory and dermal inflammation.
- ADS024: An orally dosed, naturally occurring SS-LBP with selective activation of the lysophosphatidic acid receptor 3 (LPAR3), demonstrating preclinical efficacy in neuroinflammatory disease models.
- Focus on chronic and progressive inflammatory diseases with high unmet need for targeted therapies.
- Each program (ADS051, ADS032, ADS024) has standalone comprehensive patent portfolios.